hFcRn(SD)

Gene Summary

Model Description

The endogenous rat Fcgrt gene was replaced by human FCGRT gene.
Research Application: cancer research,Immunotherapy,drug screening
*Literature published using this strain should indicate: hFcRn(SD) rats (Cat. NO. NR-HU-200002) were purchased from Shanghai Model Organisms Center, Inc..

Validation Data



Fig1. Expression characterization of hFCRN in hFCRN knockin rat by Western blot.

Abbr. HO, homozygous; WT, wild type.



Fig2. PK study of Keytruda in hFCRN rat.



Fig3. PK study of Cyramza in hFCRN rat.

Martix	Dose (mg/kg)	Group	Test articles	$T_{1/2}$	T_{max}	C_{max}	AUC_{last}	$AUC_{0-\infty}$	Cl	MRT_{last}
				h	h	μg/mL	h*μg/mL	h*μg/mL	mL/h/kg	h
Serum	13	G1	TA	162	0.50	299	26505	27875	0.47	159
		G2	TA-YTE	226	0.50	290	33743	38646	0.34	201
		G3	TA-N434A	378	0.50	328	43592	52243	0.26	205

Table 1 Pharmacokinetic parameters of test articles in hFcRn/hALB dKI rats.



Fig.4 Blood concentration curve of test articles in hFcRn/hALB dKI rats (NR-HU-233317), which were generated by crossing hFCRN(SD)(NR-HU-200002) with hALB(SD)(NR-HU-200001).

In hFcRn/hALB dKI rats, the half-life time: TA-N434A > TA-YTE > TA. (In cooperation with the third party)



Fig.5 PK study of Keytruda in hALB/hFCRN dKl rat (NR-HU-233317), which were generated by

crossing hFCRN(SD)(NR-HU-200002) with hALB(SD)(NR-HU-200001). (n=3/time point/group)



Fig.6 PK study of Cyramza in hALB/hFCRN dKI rat(NR-HU-233317), which were generated by crossing hFCRN(SD)(NR-HU-200002) with hALB(SD)(NR-HU-200001). (n=3/time point/group)